ArriVent BioPharma, Inc.

Equities

AVBP

US04272N1028

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
16.95 ^USD	-3.03%		-3.20%	0.00%

06-24	ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Global BMI Index	CI
06-05	ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	MT

ArriVent BioPharma, Inc. has completed an IPO in the amount of $174.999996 million.

January 25, 2024 at 12:00 am

ArriVent BioPharma, Inc. has completed an IPO in the amount of $174.999996 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 9,722,222
PriceRange: $18
Discount Per Security: $1.26

Transaction Features: Sponsor Backed Offering

Latest news about ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Global BMI Index	06-23	CI
ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment	06-05	MT
Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates	06-05	MT
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Enters into Research and Collaboration Agreement with Arrivent Biopharma, Inc	06-05	CI
ArriVent BioPharma, Inc. Appoints John Hohneker as Board of Directors	05-16	CI
ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
HC Wainwright Initiates ArriVent BioPharma With Buy Rating, $25 Price Target	04-30	MT
ArriVent BioPharma, Inc. Appoints Kristine Peterson to Its Board of Directors	04-22	CI
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P TMI Index	03-17	CI
LifeSci Capital Starts ArriVent BioPharma With Outperform Rating, $33 Price Target	02-20	MT
Citigroup Starts ArriVent BioPharma With Buy Rating, $30 Price Target	02-20	MT
Jefferies Starts ArriVent BioPharma With Buy Rating, $35 Price Target	02-20	MT
Goldman Sachs Initiates ArriVent BioPharma With Buy Rating, Price Target is $27	02-20	MT
Arrivent Biopharma Insider Bought Shares Worth $7,999,992, According to a Recent SEC Filing	01-31	MT
Arrivent Biopharma Insider Bought Shares Worth $7,999,992, According to a Recent SEC Filing	01-31	MT
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to NASDAQ Composite Index	01-29	CI
ArriVent BioPharma, Inc. has completed an IPO in the amount of $174.999996 million.	01-25	CI

Chart ArriVent BioPharma, Inc.

Duration

Period

More charts

Company Profile

ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.95 USD

Average target price

30.2 USD

Spread / Average Target

+78.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARRIVENT BIOPHARMA, INC.	0.00%	568M
MODERNA, INC.	+23.13%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.73%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	31.01B
CELLTRION, INC.	-12.26%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.57%	25.88B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+32.23%	12.53B
BIO-TECHNE CORPORATION	-6.56%	11.36B

Other Biotechnology & Medical Research